Pro Medicus (ASX:PME) Is Up 10.0% After EPS Jump And Dividend Hike Has The Bull Case Changed?

• Pro Medicus Limited recently reported full-year 2026 results, with sales of A$261.69 million, revenue of A$270.75 million and net income of A$265.34 million, alongside sharply higher earnings per share versus the prior year.
• The company also increased its ordinary dividend to A$0.37 per share for the year, signalling confidence in its cash generation and balance sheet strength.
• With earnings rising strongly and the full-year dividend lifted to A$0.37, we’ll explore how this update reshapes Pro Medicus’s investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Pro Medicus Investment Narrative Recap

To own Pro Medicus, you need to believe its premium imaging software can keep winning large health systems and sustain high margins despite intense competition and U.S. hospital budget pressure. The latest result, with A$270.75 million in revenue and A$265.34 million in net income, reinforces the short term catalyst of strong earnings delivery, but does not remove the key risk that any slowdown in U.S. imaging volumes or contract wins could quickly challenge today’s high expectations.

The full year dividend increase to A$0.37 per share is the most relevant update here, as it sits alongside very high profitability and a history of buybacks. Together, these capital returns highlight how much Pro Medicus currently converts earnings into cash, which matters for investors weighing its premium valuation against catalysts such as new cardiology and digital pathology contracts and the risk that large U.S. clients eventually push harder on pricing.

Yet against these strong numbers, investors should still be aware that Pro Medicus’ heavy reliance on a concentrated U.S. customer base...

Read the full narrative on Pro Medicus (it's free!)

Pro Medicus' narrative projects A$453.7 million revenue and A$259.5 million earnings by 2029. This requires 23.5% yearly revenue growth and about A$24.8 million earnings increase from A$234.7 million today.

Uncover how Pro Medicus' forecasts yield a A$190.74 fair value, in line with its current price.

Exploring Other Perspectives

Before this result, the most optimistic analysts were already assuming revenue of about A$553.8 million and earnings of A$318.1 million by 2029, which is a far more bullish path than the consensus view. With such different expectations in play, and given how dependent those forecasts are on Pro Medicus defending premium pricing in the U.S., this latest earnings jump could lead you to reassess which narrative feels more reasonable for you.

Explore 10 other fair value estimates on Pro Medicus - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pro Medicus research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Pro Medicus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pro Medicus' overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com